Filtered de novo assembly of all species (Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii) from 6-month study of two ICUs in Hanoi, Vietnam.
During a multicenter, open-label Phase 3 clinical trial of lascufloxacin intravenously administered to patients with respiratory tract infections, 17 of aspiration pneumonia and 11 of lung abscess pat
